For UK MedTech companies
The wrong UK distributor can lock you out of your own market for years
Exclusivity clauses, misaligned incentives, and under-resourced sales teams are common, and fixable before you sign. Most companies only discover the problem after the contract is in place.
Two minutes. Solva follows up with specific partner evaluation options.
- Missed sales targets and slow market penetration
- Frequent disputes over contract terms and performance
- High staff turnover within the distributor's sales team
- Negative feedback from clinicians regarding product support or availability
- Inefficient supply chain management and stockouts
- Increased administrative burden due to managing underperforming partners
- Loss of potential revenue and market share
- Significant legal costs associated with contract disputes or termination
- Delayed patient access to innovative technologies
- Suboptimal patient outcomes due to inadequate product training or support
- Negative perception among key opinion leaders and healthcare providers
- Erosion of brand trust and credibility in the UK market
No verified UK data available
Source: No verified UK data available
Frequently asked questions
Why does this problem persist?
Selecting the wrong distribution partner is one of the most costly mistakes a MedTech company can make. A poor distributor relationship can lock up your market access for years through exclusivity clauses, damage your brand through poor clinical support, and prevent you from building direct relationships with key opinion leaders. The UK MedTech distribution landscape is fragmented, with hundreds of distributors ranging from national generalists to specialist niche players, and the right partner depends on your product category, target customer, and commercial model.
What is the cost of leaving it unaddressed?
No verified UK data available
This is exactly what I do with UK private practices. Answer the few questions above and I'll come back personally with where to start. Paul.